Efficient syntheses of a novel 5-thia-1-azacycl[3.3.2]azine ring system and 3H-1,4-diazacycl[3.3.2]azine derivatives

Tetrahedron Letters

Volumn 41, Issue 18, 2000, Pages 3447-3451

  Kawamoto, Tetsuji ^a   Tomimatsu, Kiminori ^a   Ikemoto, Tomomi ^a   Abe, Hidenori ^a   Hamamura, Kazumasa ^a   Takatani, Muneo ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

3 (trichloroacetyl)imidazo 1,2 a pyridine; 3H 1,4 diazacycl 3.3.2 azine; 4,5,dihydro 3H 1,4,8b triazaacenaphthylen 3 one; 4,5 dihydro 3H 1,4,8b triazaacenaphthylene 3,5 dione; 5 thia 1,8b diazaacenaphthylene; 5 thia 1 azacycl 3.3.2 azine

Indexed keywords

ACENAPHTHENE DERIVATIVE; CYCLAZINE DERIVATIVE; IMIDAZO[1,2 A]PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CRYSTAL STRUCTURE; DRUG SYNTHESIS; PROTON NUCLEAR MAGNETIC RESONANCE; REACTION ANALYSIS; X RAY CRYSTALLOGRAPHY;

EID: 0034728897     PISSN: 00404039     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0040-4039(00)00426-3     Document Type: Article

References (39)

1. (a) Taurins, A. In The Chemistry of Heterocyclic Compounds; Weissberger, A.; Taylor, E. C., Eds.; John Wiley: New York, 1977; Vol. 30, pp. 245-270.
2. (b) Flitsch, W.; Krämer, U. In Advances Heterocyclic Chemistry; Katritzky, A. R.; Boulton, A. J., Eds.; Academic Press: New York, 1978; Vol. 22, pp. 321-365.
3. (c) Flitsch, W. In Comprehensive Heterocyclic Chemistry; Katritzky, A. R.; Rees, C. W., Eds.; Pergamon Press, Oxford, 1984; Vol. 4, pp. 478-495.
4. (a) Kurihara, T.; Kerim, A.; Ohta, A. J. Heterocyclic Chem. 1994, 31, 929-933.
5. (b) Höweler, U.; Chatterjee, P. S.; Klingensmith, K. A.; Waluk, J.; Michl, J. Pure Appl. Chem. 1989, 61, 2117-2128.
6. (c) Rossman, M. A.; Leonard, N. J.; Urano, S.; Le Breton, P. R. J. Am. Chem. Soc. 1985, 107, 3884-3890.
7. (d) Shahbaz, M.; Urano, S.; Le Breton, P. R.; Rossman, M. A.; Hosmane, R. S.; Leonard, N. J. J. Am. Chem. Soc. 1984, 106, 2805-2811.
8. (e) Gotou, H.; Kurata, K.; Tominaga, Y.; Matsuda, Y. J. Org. Chem. 1985, 50, 4028-4032.
9. (f) Leaver, D.; Skinner, D. Chem. Commun. 1984, 821-822.
10. (g) Windgassen, R. J.; Saunders, W. H.; Boekelheide, V. J. Am. Chem. Soc. 1959, 81, 1459-1465.
11. (h) Galbraith, A.; Small, T.; Barnes, R. A.; Boekelheide, V. J. Am. Chem. Soc. 1961, 83, 453-458.
12. (i) Farquhar, D.; Gough, T. T.; Leaver, D. J. Chem. Soc., Perkin Trans 1 1976, 341-355.
13. Montgomery, J. A.; Secrist III, J. A. In Comprehensive Heterocyclic Chemistry; Katritzky A. R.; Rees, C. W., Eds.; Pergamon Press: Oxford, 1984; Vol. 5, pp. 607-668.
14. (a) As ligands for benzodiazepine receptors, see: Langer, S. Z.; Arbilla, S.; Benavides, J.; Scatton, B. In GABA and Benzodiazepine Receptor Subtypes; Biggio, G., Costa, E., Eds.; Raven Press: New York, 1990; pp. 61-72.
15. (b) as antiulcer agents, see: Kaminski, J. J.; Wallmark, B.; Briving, C.; Anderson, B.-M. J. Med. Chem. 1991, 34, 533-41.
16. (c) as antiviral agents, see: Gueiffier, A.; Mavel, S.; Lhassani, M.; Elhakmaoui, A.; Snoeck, R.; Andrei, G.; Chavignon, O.; Teulade, J.-C.; Witvrouw, M.; Balzarini, J.; De Clercq, E.; Chapat, J.-P. J. Med. Chem. 1998, 41, 5108-5112.
17. 2 receptor antagonists, see: Abe, Y.; Kayakiri, H.; Satoh, S.; Inoue, T.; Sawada, Y.; Imai, K.; Inamura, N.; Asano, M.; Hatori, C.; Katayama, A.; Oku, T.; Tanaka, H. J. Med. Chem. 1998, 41, 564-578.
18. (e) as bone resorption inhibitors, see: Kawai, Y.; Satoh, S.; Yamazaki, H.; Kayakiri, N.; Yoshihara, K.; Oku, T. PCT Int. Appl. WO 9634866, 1996; Chem. Abstr. 1998, 126, 74840.
19. Hodgkiss, R. J.; Middleton, R. W.; Parrick, J.; Rami, H. K.; Wardman, P.; Wilson, G. D. J. Med. Chem. 1992, 35, 1920-1926.
20. Lerner, D. A.; Horowitz, P. M.; Evleth, E. M. J. Phys. Chem. 1977, 81, 12-17.
21. Kurata, K.; Awaya, H.; Tominaga, Y.; Matsuda, Y.; Kobayashi, G. Yakugaku Zasshi, 1978, 98, 631-635.
22. Compound 4 was prepared by treatment of 5-mercaptoimidazo[1,2-a]pyridine with ethyl bromoacetate in the presence of triethylamine in ethanol at room temperature in 95% yield.
23. (a) Bisagni, E.; Rautureau, M.; Heul, C. Heterocycles, 1988, 27, 1671-1678.
24. (b) Verbiscar, A. J. J. Med. Chem. 1972, 15, 149-152.
25. Almirante, L.; Mugnaimi, A.; De Toma, N.; Gamba, A.; Murmann, W. J. Med. Chem. 1970, 13, 1048-1051.
26. About 45% of 4 (as 4·HCl) was recovered. The resulting 4·HCl in the reaction would not undergo formylation at C(3) with the Vilsmeier's reagent due to low electron density at the C(3) position.
27. 3; Rw=0.106. Final crystallographic coordinates, bond distances, bond angles, structure factors, and thermal parameters have been deposited with, and can be ordered from, the Cambridge Crystallographic Data Centre.
28. (a) Hordvik, A.; Kjøge, H. M. Acta Chem. Scand. 1965, 19, 935-946.
29. (b) Hordvik, A.; Sletten, J. Acta Chem. Scand. 1966, 20, 1907-1922.
30. (c) McEwen, R. S.; Sim, G. A. J. Chem. Soc. (A) 1967, 271-275.
31. Compound 6 was prepared by treatment of 5-mercaptoimidazo[1,2-a]pyridine with bromoacetaldehyde dimethyl acetal in the presence of N,N-diisopropyl-N-ethylamine in ethanol in 70%.
32. Teulade, J. C.; Bonnet, P. A.; Rieu, J. N.; Viols, H.; Chapat, J. P.; Grassy, G.; Carpy, A. J. Chem. Res. (M) 1986, 1842-1874.
33. Compound 9 was prepared by treatment of 8 with acetic anhydride in the presence of DMAP in acetonitrile in 95%.
34. 2S: C, 62.05; H, 3.47; N, 16.08. Found: C, 62.05; H, 3.47; N, 16.09.
35. (a) Selby, T. P. J. Org. Chem. 1988, 53, 2386-2388.
36. (b) Kanemasa, S.; Nakamura, S.; Kajigaeshi, S. Chem. Lett. 1980, 947-950.
37. Hand, E. S.; Paudler, W. W. J. Org. Chem. 1976, 41, 3549-3556.
38. Hofle, G.; Steglich, W.; Vorbruggen, H. Angew. Chem., Int. Ed. Engl. 1978, 17, 569-583. Guibe-Jampel, E.; Le Corre, G.; Wakselman, M. Tetrahedron Lett. 1979, 1157-1160.
39. Hofle, G.; Steglich, W.; Vorbruggen, H. Angew. Chem., Int. Ed. Engl. 1978, 17, 569-583. Guibe-Jampel, E.; Le Corre, G.; Wakselman, M. Tetrahedron Lett. 1979, 1157-1160.